Last reviewed · How we verify
NeisVac C vaccine (12mth)
NeisVac C is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C polysaccharide capsule.
NeisVac C is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants and children.
At a glance
| Generic name | NeisVac C vaccine (12mth) |
|---|---|
| Also known as | NeisVac C vaccine (Baxter), Meningococcal C congugate vaccine |
| Sponsor | University of British Columbia |
| Drug class | Meningococcal conjugate vaccine |
| Target | Neisseria meningitidis serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified polysaccharide from the meningococcal serogroup C capsule conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This allows the vaccine to induce both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by serogroup C strains. The conjugate formulation is particularly effective in infants and young children who would otherwise have poor response to unconjugated polysaccharide vaccines.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants and young children
Common side effects
- Local injection site reactions (erythema, swelling, pain)
- Fever
- Irritability
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeisVac C vaccine (12mth) CI brief — competitive landscape report
- NeisVac C vaccine (12mth) updates RSS · CI watch RSS
- University of British Columbia portfolio CI